

HHS Public Access

JAm Acad Dermatol. Author manuscript; available in PMC 2016 August 23.

Published in final edited form as:

Author manuscript

JAm Acad Dermatol. 2008 November ; 59(5): 758–771. doi:10.1016/j.jaad.2008.07.018.

A GENE SIGNATURE OF NON-HEALING VENOUS ULCERS: POTENTIAL DIAGNOSTIC MARKERS

Carlos A. Charles, MD¹, Marjana Tomic-Canic, PhD^{4,5}, Vladimir Vincek, MD, PhD^{1,3}, Mehdi Nassiri, MD³, Olivera Stojadinovic, MD⁴, William H. Eaglstein, MD¹, and Robert S. Kirsner, MD, PhD^{1,2}

¹Department of Dermatology and Cutaneous Surgery, University of Miami School of Medicine, Miami, Florida, USA

²Department of Epidemiology and Public Health, University of Miami School of Medicine, Miami, Florida, USA

³Department of Pathology, University of Miami School of Medicine, Miami, Florida, USA

⁴Tissue Repair Lab, Tissue Engineering, Regeneration and Repair Program, Hospital for Special Surgery of the Weill Medical College of Cornell University, New York, NY 10021, USA

⁵ Department of Dermatology, Weill Medical College of Cornell University, New York, NY 10021, USA

Abstract

Background—Venous leg ulcers are responsible for more than half of all lower extremity ulcerations. Significant interest has been focused on understanding the physiologic basis upon which patients fail to heal with standard therapy.

Objective—This study uses complementary DNA microarray analysis of tissue samples from healing and non-healing venous leg ulcers to identify the genetic expression profiles from these dichotomous populations.

Methods—Ulcer size and chronicity, factors that have been identified as prognostic indicators for healing, were used to distribute venous leg ulcers as healing versus non-healing. Punch biopsy samples were obtained from the wound edge and wound bed of all venous leg ulcers. The top fifteen genes with differential expression greater than twofold between the two populations of wounds (p < 0.05) were reported.

Results—Significant differences were demonstrated in the expression of a diverse collection of genes, with particular differences demonstrated by genes coding for structural epidermal proteins, genes associated with hyperproliferation and tissue injury, as well as transcription factors.

Correspondence: Robert S. Kirsner, M.D., PhD, Professor & Vice Chairman, Department of Dermatology & Cutaneous Surgery, University of Miami Miller School of Medicine, 1600 N.W. 10th Avenue, RMSB, Room 2023-A, Miami, Florida 33136, 305 243 4472 (office), 305 243 6191 (fax), Rkirsner@med.miami.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Limitations—Small sample size may mitigate potential clinical implications of findings.

Conclusions—The genetic expression profiles displayed here may have implications for the development of novel therapies for chronic venous leg ulcers, and may also serve as prognostic indicators for wound healing.

INTRODUCTION

Venous leg ulcers are responsible for more than half of all lower extremity ulcerations, affecting over one million Americans annually with an annual cost upward of \$2.5 billion dollars (1). The standard of care, multi-layered compression bandages, is effective in only one half to two thirds of patients (2-3). Significant interest has focused on understanding the population of patients who fail to heal with standard therapy. Several theories have suggested that the development of senescent cells within and at the wound edge, deficiency or lack of availability of cytokines or their receptors, and/or the presence of an abnormal wound bed matrix may be responsible for wound chronicity (4-7). Essential to our understanding of wound healing is knowledge of the genetic signals that lead to wound healing progression (8).

Studies have used high-density cDNA microarrays to delineate the gene expression of normal human skin (9-10) and early gene expression profiles of human skin following injury (11-13). Analysis of normal human skin found variability of genetic expression in 1.7% of the genes studied, these included genes coding for transport proteins, transcription, cell signaling proteins, and cell surface proteins. Little variability was identified in the wound matrix genes, growth factor genes and other groups of genes commonly thought to be involved in wound healing, suggesting that any newly identified expressed genes may be important to the wound healing process. Microarray analysis of injured human skin found expression of several genes historically unappreciated in the study of wound healing, specifically cytokine suppressor genes. Furthermore, microarray analysis has been performed to study the temporal analysis of gene expression in wound healing in an animal model, in which the temporal gene expression profile of wound healing was studied in the ear-punched tissue of mice (14). This study identified expression of genes principally related to the inflammatory stage that had not previously been associated with wound healing. Recent microarray study of biopsies of venous ulcers from two different wound edge locations (prior and post debridement) identified distinct wound region that may be better responsive to therapy (15). Finally, the study comparing biopsies obtained from a non – healing edges of venous ulcers to healthy, normal skin revealed de-regulation of keratinocytes activation and differentiation pathways in the epidermis deriving from a venous ulcers non - healing edges (16). In sum, the high-throughput analysis of gene expression by microarray technology in wound healing models has provided for the identification of novel genes that may play a critical role in non-healing.

In the present study we used high throughput cDNA microarray analysis to examine the patterns of local genetic expression to in order compare healing and non-healing chronic venous leg ulcers. Taking advantage of well-described prognostic indicators for wound healing in venous leg ulcers, ulcer size and duration; we grouped wounds into healing and

non-healing groups (17-18). Using biopsy samples obtained from these dichotomous populations of chronic venous leg ulcers, we analyzed genetic expression from keratinocytes, fibroblasts, and other cells, from within the tissue sampled using the microarray technique.

MATERIALS AND METHODS

Subjects

Patients were recruited according to a protocol approved by the University of Miami School of Medicine Institutional Review Board. Consent was obtained from all patients, and the Declaration of Helsinki protocols were followed. Five patients with non-healing and five patients with healing chronic venous leg ulcers as defined by previous prognostic models for wound healing in venous leg ulcers were studied (17-18). All ulcers were present for at least 4 weeks. Healing venous leg ulcers were defined as ulcers that were less than 5cm^2 in surface area and present for less than 6 months, while non-healing ulcers was determined clinically and confirmed by vascular studies, if needed. Clinical parameters used to identify venous leg ulcers were the presence of a lower leg ulcer and at least two of the following: dermatitis, atrophie blanche, varicosities, hyperpigmentation, or lipodermatosclerosis. If these were not present, patients were studied with duplex venous Doppler ultrasound to document venous insufficiency. Patients with moderate to severe arterial disease were excluded, initially by an ankle brachial index (<0.9) and if needed, by pulse volume recordings.

Under local anesthesia, two 4-millimeter punch biopsy specimens were obtained from each venous leg ulcer: one from the wound margin, one from the center of the wound bed. All wounds were subsequently treated as per standard of care for chronic venous leg ulcers (19). Tissue samples were processed using a fixative based on polyethylene glycol and methanol (Universal Molecule Fixative) that preserves the tissue morphology as well as the integrity of the nucleic acids, including DNA and RNA (20).

RNA Extraction and Labeling

Total RNA extraction was performed by addition of Trizol reagent (GibcoBRL, Gaithersburg, MD) and subsequent homogenization using a Tissue Tearor (Biospec Products Inc, Bartlesville, OK). The RNA from homogenized tissue was extracted with chloroform followed by isopropyl precipitation on ice. The RNA pellets were re-suspended in 100 ml of diethylpyrocarbonate (DEPC)-treated water. Standard 1% agarose gel under denaturing condition with ethidium bromide was used to assess the integrity of RNA. In addition, RNA was run on an Agilent Technologies Bioanalyzer 2100 using RNA 6000 Nano Chips (Lindenhurst, NY) to determine RNA integrity and the ratio of ribosomal RNA. The quantity of the extracted RNA was determined by spectrophotometery (Ultraspec III, Pharmacia, Netherlands). RNA samples were analyzed at Expression Analysis Inc (Durham, NC) using Affymetrix (Santa Clara, CA) Human Genome U133 PLUS 2.0 Array and supporting kits and protocols for preparation of template and hybridization. Shortly, two micrograms of total RNA was used to synthesize double-stranded cDNA using One-Cycle cDNA Synthesis Kit

(Affymetrix) following manufacturer's instructions. In vitro transcription amplification and biotin labeling to prepare targets for arrays was performed using Affymetrix GeneChip IVT Labeling Kit following their protocol. Biotinylated cRNA was cleaned using GeneChip Sample Cleanup Module (Affymetrix). After hybridization for 16 hours, microarrays were washed and stained using Affymetrix standard protocol. Scanned images were processed and analyzed using Affymetrix GCOS software. Two group comparison was done on normalized expression values that were individually transformed using base 2 logarithm of the expression index. On log–transformed scale, the mean was calculated for every probe set within each group and a two sample, two-sided t-test was conducted (MS Excel)

Image Analysis

Following hybridizaton, an Axon GenePix 4000 scanner was used to scan slides and background-subtracted feature intensity was calculated. Quality criteria for inclusion in the data set for further analysis included signal to background > 3, no more than 20% missing or saturated pixels, and a minimum background subtracted signal level > 50. Intensity data was normalized and evaluated using GEMTools software.

Data Analysis

Duplicate hybridizations were performed on microarrays made by Affymetrix ® containing over 47,000 transcripts.

The difference ratios between the signals in healing and non-healing ulcer samples were then calculated for the subset of cases with complete and incomplete responses, identifying those genes that were most different between the two. Gene features that exhibited at least a twofold difference in intensity ratio with respect to the reference RNA in at least 2 wounds were selected for further analysis. A first pass analysis evaluated a 2-cluster classification, using k-means methods, on progressively smaller sets of genes to identify a set with maximum distance between groups. The list was narrowed based on the correlation response. Such analysis (e.g. bootstrapping and/or leave-one-out cross validation) was performed until an optimal group of genes was identified that correlated with wound chronicity or healing. Once duplicates were eliminated top 15 regulated (induced and down-regulated) are selected and presented in the tables. Disease associations and gene functions were obtained from several gene and genome search engines: http://smd.stanford.edu/cgi-bin/source/sourceResult; http://genome-www.stanford.edu/genecards/index.shtml; http:// www.dsi.univ-paris5.fr/genatlas/

RESULTS AND DISCUSSION

Optimal wound healing depends upon the concerted interplay of thousands of genes. Of those identified to be differently expressed between these two groups of venous leg ulcers, several specific genes deserve special mention.

Gene Expression Profile of Healing versus Non-Healing Epidermal Wound Edge

Tables 1 and 2 demonstrate the top fifteen genes that were differentially expressed between the two groups of venous leg ulcers from the keratinocytes of the tissue sampled at the non-

healing wound edge. The most striking finding in this data set is the extent to which genes implicated in epidermal hyperproliferation and tissue repair were differentially expressed. Of additional interest is that the down- regulation (> 250.00) demonstrated in the non-healing wound edges was much greater than the up- regulation (>10.00) evidenced by the non-healing wounds.

The top activated gene in non-healing edges is secreted frizzled-related protein 4 (SFRP4), a mediator of Wnt signaling. Furthermore, branched chain aminotransferase 1 (BCAT1) was also found up-regulated, and this gene has been associated with c-myc induced tumors. These findings are consistent with previous findings of activation of b-catenin and c-myc in non-healing edges of venous ulcers (16). Another novel finding revealed up- regulation of cytochrome P450 (CYP1B1) and 17-beta-hydroxisteroid dehydrogenase VI (HSD17B6), genes associated with steroidogenesis. CYP1B1 has been found induced in keratinocytes upon challenge with UVB (21-22). Up- regulation of steroidogenesis associated genes suggests that steroid synthesis and metabolism may participate in the pathogenesis of non – healing ulcers . Secreted frizzled-related protein 4 have shown increased expression in disease processes associated with increased cell death (23), particularly those where apoptosis is occurring, such as heart failure and degenerative retinal disease and this propensity for cellular apoptotosis may have implications for impaired tissue regeneration in wound healing. Furthermore, adhesion molecules such as selectin E (SELE) have been shown to be expressed on activated endothelium and platelets at sites of vascular injury and inflammation. P and E selectin have been associated with microvascular dysfunction in chronic venous insufficiency, and studies have identified the importance of their combined roles in the process of wound healing (24). A study of mice deficient in both P- and Eselectins demonstrated markedly reduced recruitment of inflammatory cells and impaired wound clousure. Additionally, a wider epithelial gap was observed in the wounds of the Pand E-selectin-double-deficient mice 3 days after wounding indicating delayed keratinocyte migration.

Of the top twenty genes down- regulated more than 2 fold in the non-healing wound edge, majority genes express protein products that are considered crucial to epidermal structural integrity or are associated with epidermal injury, repair, hyperproliferation and or differentiation. Interestingly, the predominant gene group that is down-regulated are keratins. The gene that demonstrated the greatest downregulation in the non-healing epidermal wound edge was that which codes for keratin 16 (KRT16) (-258.78), a gene product that has been associated with cutaneous injury and timely epidermal repair (25). Two of its heterodimeric partners, keratin 6A (KRT6A) (-61.50) and 6B (KRT6B) (-43.98), which are thought to play an important role in epidermal regeneration and have been shown to be over-expressed in cutaneous injury and epithelial repair, demonstrated significant downregulation in the non-healing venous ulcer edges (26). Closely functionally related is also keratin 17 (KRT17) which is also participating in epidermal repair and may also play a role in contractility. Keratinocyte migration is also deficient in chronic wounds (16). Keratins K16, K6a, K6b and K17 play a role in epithelial migration and their downregulation may contribute to lack of epithelial migration. Finally, keratins K14 and K1 were also found down- regulated. Keratin K14 is basal layer specific and demarcates the mitotically active compartment whereas keratin 1 demarcates differentiating keratins. Thus,

keratins marking all three epidermal phenotypes: basal, differentiating and activated (wound-healing like) were down- regulated, further suggesting that all three biological processes essential for maintenance of epidermis are affected. Furthermore, a cluster of differentiation associated genes that participate in stratification, cornification and desmosome formation (stratifin (SFN), cornifin (CFN), filaggrin (FIL) and desmoplakin (DSP)) were also found to be down- regulated, suggesting that differentiation process is not properly executed. This data are in agreement with our previous findings of de-regulation of differentiation in non-healing edges of venous ulcers when compared to healthy skin (16). Other genes that deserve attention in these top twenty down- regulated genes demonstrated in the non-healing wound edges are the skin-derived anti leukoproteinase(SKALP/elafin) (-126.11), S100 calcium binding protein A7 (S100A7) (-120.44), and Aquaporin 3 (AQP3) (-48.01). The SKALP/elafin gene has been described as an epidermal proteinase inhibitor (27). It is absent in the normal epidermis, however it has been shown to be expressed following epidermal injury and is also present in inflammatory skin conditions such as psoriasis. The exact physiologic role of SKALP/elafin is unknown; however it has been associated with cutaneous homeostasis involved in the regulation of inflammation via neutrophilic regulation. The S100A7 gene expresses the protein products that have been proposed to be involved in keratinocyte differentiation. This is a family of calcium-activated signaling proteins that interact with target proteins to modulate skin disease and their levels are markedly elevated in psoriatic epidermis, suggesting a role in epidermal proliferation (28). The Aquaporin 3 gene expresses for aquaporins, which are a family of small water and/or glycerol transmembrane channels. Eleven mammalian aquaporins have been described so far. Specifically, AQ3 is an aquaglyceroporin with expression in the kidney collecting cells, red cells, dendritic and epithelial cells. Aquaporin 3 deficient mice demonstrate delayed wound healing with decreased epidermal water and glycerol content and decreased skin elasticity (29).

It is quite surprising that none of the genes that are classically thought to be involved in stimulating wound repair, such as those which encode for platelet-derived growth factor or keratinocyte growth factor, were significantly down- regulated in the non-healing epidermal wound edges.

Gene Expression Profile of Healing versus Non-Healing Dermal Wound Bed

Tables 3 and 4 demonstrate the top fifteen genes that were differentially expressed between the two groups of venous leg ulcers from the cells sampled at the wound bed. Interestingly, the extent of differential gene expression between the two groups of ulcers is much less than that seen in the wound edge cells. This piece of data may be indicative of the importance of proper epithelial migration for appropriate wound closure.

The tissue sampled from the non-healing wound bed also demonstrated a heterogeneous group of genes that were up- regulated greater than two-fold. The gene that demonstrated the greatest extent of up- regulation, properdin (BF) (+8.41), codes for a factor of the alternative pathway of complement activation known as complement factor B, implicating an association between immune function and optimal wound healing. In addition, strong properdin induction was noticed by turbulent flow and possibly associated with

atherosclerosis (30) Additionally, of the top twenty up- regulated genes from non-healing dermal wound bed cells, several code for proteins that have been directly associated with tissue injury, extracellular matrix formation, and the wound healing process. The extracellular matrix protein dermatopontin (DPT) (+7.77) has been shown to play a critical role in tissue elasticity and collagen accumulation necessary for collagen fibrillogenesis in in vivo murine wound healing models (31). Additionally, transforming growth factor-beta 1 can increase the expression of dermatopontin in normal cultured human skin fibroblasts indicating a potential association between dermatopontin and cytokines critical in the wound healing process (32). Another important group of extracellular matrix proteins important in the wound healing process are the fibulins. Fibulin 1 (FBLN1) (+3.50) has been found to be present in normal skin granulation tissue and wounds; but has not been shown to be distinctly up- regulated during the healing process of murine wounds (33). Two other genes that deserve special mention in this group of upregulated genes are thrombospondin 1 (THBS1) (+3.39) and platelet-derived growth factor receptor (PDGFRA) (+3.36). The protein encoded by thrombospondin 1 is a multifunctional extracellular matrix molecule that has been shown to be involved in re-epithelialization as well as dermal reorganization in murine wound models (34). Additionally, this matricellular glycoprotein has been associated with skin angiogenesis through its interactions with the cytokine vascular endothelial growth factor (35). Lastly, the association between platelet-derived growth factor (PDGF) and wound healing has been well described.

The tissue sampled from the wound bed demonstrated a diverse array of genes that were also down- regulated greater than two-fold. A number of these genes also deserve special mention. The gene that encodes for the protein kazrin (KIAA1026) (-2.75) may be important for epidermal repair and the wound healing process. Kazrin is a novel component of desmosomes that associates with periplakin (36). Interestingly, two tumor suppressor genes were significantly down- regulated in this non-healing population of wounds, retinoblastoma binding protein 6 (RBBP6) (-2.57) and SAM and SH3 domain containing 1 (SASH1) (-2.49), implicating a role of altered cell cycle regulation in normal wound healing. A novel macrophage expressed gene 1 (MPEG1) (-2.48) was found downregulated in a wound bed of non – healing ulcers. Macrophages play an important role in the adult inflammatory response to wounding and are responsible for cellular debridement. They recruit other inflammatory and fibroblastic cells and influence cell proliferation and tissue remodeling as a source of growth factors and cytokines (37). Interestingly, a disintegrinlike and metalloproteinase with trombospondin type 1 motif, 14 (ADAMTS14) (-2.27) was found down- regulated as well. Down- regulation of ADAMTS-14 in a wound bed of nonhealing wounds may play a role in decreased collagen synthesis and consequently to improper wound bed formation. Lastly, of great importance, down- regulation was demonstrated in heparin-binding epidermal growth factor – like growth factor (HBEGF) (-2.40), a gene that has clearly been associated with appropriate wound healing. Studies of wound healing have revealed that wound closure is markedly impaired in keratinocytespecific HB-EGF-deficient mice (38) and that ligand shedding of heparin-binding EGF-like growth factor is important for keratinocyte migration and proper wound epithelialization (39). Furthermore, HB-EGF has been shown to be a major growth factor component of wound fluid and, since it is mitogenic for fibroblasts and keratinocytes it plays an important

role in wound healing (40) Therefore down– regulation of HB- EGF in biopsies deriving from a wound bed of non – healing ulcers can partly explain phenotype of non – healing wounds. It is noteworthy that - SMART/HDAC1 associated repressor protein (SHARP), was also down- regulated indicating that perhaps histones may be acetylated and that chromatin changes may favor transcriptional activity.

The findings of the present study demonstrate a diversity of genetic expression associated with wound healing in chronic venous leg ulcers. Altered expression was seen in genes that code for structural factors, mediators of inflammation, and apoptotic pathways. While the significance of this information is yet to be determined, this study provides a unique understanding by demonstrating that healing and non-healing venous leg ulcers do display a unique and dichotomous genetic physiology. With this information, future studies may focus on topical growth factors and/or genetically modified tissue engineered skin that may optimize the wound environment for optimal healing. Furthermore, the factors demonstrated in this study may represent physiologic prognostic indicators of wound healing and may be useful for stratifying venous leg ulcers according to their potential to heal. This may help clinicians to identify venous leg ulcers that may require advanced wound healing treatment modalities in conjunction with compression therapy at the outset of treatment. Additionally, studies should be conducted to evaluate the information described herein for the development of improved therapeutic approaches. Techniques such as reverse transcriptase real-time polymerase chain reaction may be employed to study the gene expression of a similar population of large group of venous leg ulcers to help further investigate the significance of the present findings.

In conclusion, significant differences exist in the genetic expression between healing and non-healing venous leg ulcers. These findings should help to identify the aberrant physiologic processes associated with impaired tissue repair in this population of wounds. More importantly, the genetic expression profiles displayed here may have implications for the development of novel therapies for chronic venous leg ulcers, and may also serve as prognostic indicators for healing.

AKNOWLEDGMENTS

Our research is supported by the National Institutes of Health grants NR008029; AG030673 and a pilot award from the UL1RR024996 Center for Translational Science Award of the Weill Cornell Medical College.

References

- 1. Valencia IC, Falabella A, Kirsner RS, Eaglstein WH. Chronic venous insufficiency and venous leg ulceration. J Am Acad Dermatol. 2001; 44:401–421. [PubMed: 11209109]
- Falanga V, Margolis D, Alvarez O, et al. Healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Arch Dermatol. 1998; 134:293–300. [PubMed: 9521027]
- 3. Phillips TJ. Successful methods of treating venous ulcers: the tried and true, plus the novel and new. Postgrad Med. 1999; 105:159–179. [PubMed: 10335328]
- Stanley A, Osler T. Senescence and the healing rates of venous ulcers. J Vasc Surg. 2001; 33:1206– 1211. [PubMed: 11389419]

- Mendez MV, Raffetto JD, Phillips T, Menzoian JO, Park HY. The proliferative capacity of neonatal skin fibroblasts is reduced after exposure to venous ulcer wound fluid: A potential mechanism for senescence in venous ulcers. J Vasc Surg. 1999; 30:734–743. [PubMed: 10514213]
- Schäfer M, Werner S. Transcriptional control of wound repair. Annu Rev Cell Dev Biol. 2007; 723:69–92. [PubMed: 17474876]
- Raja, Sivamani K, Garcia MS, Isseroff RR. Wound re-epithelialization: modulating keratinocyte migration in wound healing. Front Biosc. 2007; 12:2849–68.
- Martin P. Wound Healing: Aiming for perfect skin regeneration. Science. 1997; 276:75–81. [PubMed: 9082989]
- 9. Cole J, Tsou R, Wallace K, Gibran N, Isik F. Comparison of normal human skin gene expression using cDNA microarrays. Wound Rep Reg. 2001; 9:77–85.
- Gazel A, Ramphal P, Rosdy M, et al. Transcriptional profiling of epidermal keratinocytes: comparison of genes expressed in skin, cultured keratinocytes, and reconstituted epidermis, using large DNA microarrays. J Invest Dermatol. 2003; 121:1459–68. [PubMed: 14675197]
- Cole J, Tsou R, Wallace K, Girbran N, Isik F. Early gene expression profile of human skin to injury using high-density cDNA microarrays. Wound Rep Reg. 2001; 9:360–371.
- Tomic-Canic M, Brem H. Gene array technology and pathogenesis of chronic wounds. Am J Surg. 188(1A Suppl):67–72. 2004. [PubMed: 15223505]
- Blumenberg M, Tomic-Canic M. Gene Profiling: Implications in Dermatology) Expert Review of Dermatology. 2007; 2:763–768. [PubMed: 27525033]
- Samulewicz SJ, Seitz A, Clark L, Heber-Katz E. Expression of preadipocyte factor-1(Pref-1), a delta-like protein, in healing mouse ears. Wound Repair Regen. 2002; 10:215–221. [PubMed: 12191003]
- 15. Brem H, Stojadinovic O, Diegelmann RF, et al. Molecular markers in patients with chronic wounds to guide surgical debridement. Mol Med. 2007; 13:30–9. [PubMed: 17515955]
- 16. Stojadinovic O, Brem H, Vouthounis C, Lee B, Fallon J, Stallcup M, Merchant A, Galiano RD, Tomic-Canic M. Molecular Pathogenesis of Chronic Wounds: The Role of β-Catenin and c-myc in the Inhibition of Epithelialization and Wound Healing. Amer J Path. 2005; 167:59–69. [PubMed: 15972952]
- Margolis DJ, Berlin JA, Strom BL. Which venous leg ulcers will heal with limb compression bandages? Am J Med. 2000; 109:15–9. [PubMed: 10936473]
- Phillips TJ, Machado F, Trout R, et al. Prognostic indicators in venous ulcers. J Am Acad Dermatol. 2000; 43:627–30. [PubMed: 11004617]
- De Araujo TS, Hexsel CL, Kirsner RS. Curr Treat Options Cardiovasc Med. 2005; 7:131–138. [PubMed: 15935121]
- Vincek V, Nassiri M, Nadji M. A tissue fixative that protects macromolecules (DNA, RNA, and protein) and histomorphology in clinical samples. Lab Invest. 2003; 83:1427–1435. [PubMed: 14563944]
- 21. Villard PH, Sampol E, Elkaim JL, Puyoou F, Casanova D, Seree E, Durand A, Laca relle B. Increase of CYP1B1 transcription in human keratinocytes and HaCaT cells after UV-B exposure. Toxicol Applied Pharmacol. 2002; 178:137–143.
- Yengi LG, Xiang Q, Pan J, Scatina J, Kao J, Ball SE, Fruncillo R, Ferron G, Roland Wolff C. Quantitation of cytochrome P450 mRNA levels in human skin. Annal Biochem. 2003; 316:103– 110.
- Jones S, Jomary C. Secreted Frizzled-related proteins: searching for relationships and patterns. Bioessays. 2002; 24:811–820. [PubMed: 12210517]
- Subramaniam M, Saffaripour S, Van De Water L, Frenette PS, Mayadas TN, Hynes RO, Wagner DD. Role of endothelial selectins in wound repair. Am J Pathol. 1997; 150:1701–1709. [PubMed: 9137094]
- 25. Mazzalupo S, Wong P, Martin P, Coulombe PA. Role for keratins 6 and 17 during wound closure in embryonic mouse skin. Dev Dyn. 2003; 226:356–65. [PubMed: 12557214]
- Wojcik SM, Bundman DS, Roop DR. Delayed wound healing in keratin 6a knockout mice. Mol Cell Biol. 2000; 20:5248–5255. [PubMed: 10866680]

- Alkemade HA, Molhuizen HO, van Vlijmen-Willems IM, et al. Differential expression of SKALP/ Elafin in human epidermal tumors. Am J Pathol. 1993; 143:1679–1687. [PubMed: 8256855]
- Eckert RL, Broome AM, Ruse M, et al. S100 proteins in the epidermis. Invest Dermatol. 2004; 123:23–33.
- 29. Zheng X, Bollinger Bollag W. Aquaporin 3 colocates with phospholipase d2 in caveolin-rich membrane microdomains and is downregulated upon keratinocyte differentiation. Invest Dermatol. 2003; 121:1487–1495.
- Bongrazio M, Pries AR, Zakrzewicz A. The endothelium as physiological source of properdin: role of wall shear stress. Mol Immunol. 2003; 39:669–75. [PubMed: 12493642]
- Takeda U, Utani A, Wu J. Targeted disruption of dermatopontin causes abnormal collagen fibrillogenesis. J Invest Dermatol. 2002; 119:678–683. [PubMed: 12230512]
- 32. Kuroda K, Okamoto O, Shinkai H. Dermatopontin expression is decreased in hypertrophic scar and systemic sclerosis skin fibroblasts and is regulated by transforming growth factor-beta1, interleukin-4, and matrix collagen. J Invest Dermatol. 1999; 112:706–10. [PubMed: 10233760]
- Fassler R, Sasaki T, Timpl R. Differential regulation of fibulin, tenascin-C, and nidogen expression during wound healing of normal and glucocorticoid-treated mice. Exp Cell Res. 1996; 222:111– 116. [PubMed: 8549652]
- DiPietro LA, Nissen NN, Gamelli RL. Thrombospondin 1 synthesis and function in wound repair. Am J Pathol. 1996; 148:1851–1860. [PubMed: 8669471]
- Detmar M. The role of VEGF and thrombospondins in skin angiogenesis. J Dermatol Sci. 2000; 24(Suppl 1):S78–84. [PubMed: 11137400]
- Groot KR, Sevilla LM, Nishi K. Kazrin, a novel periplakin-interacting protein associated with desmosomes and the keratinocyte plasma membrane. J Cell Biol. 2004; 30(166):653–659. [PubMed: 15337775]
- Hopkinson-Woolley J, Hughes D, Gordon S, Martin P. Macrophage recruitment during limb development and wound healing in the embryonic and foetal mouse. J Cell Sci. 1994; 107:1159– 1167. [PubMed: 7929625]
- 38. Shirakata Y, Kimura R, Nanba D. Heparin-binding EGF-like growth factor accelerates keratinocyte migration and skin wound healing. J Cell Sci. 2005; 118:2363–70. [PubMed: 15923649]
- Tokumaru S, Higashiyama S, Endo T, Nakagawa T, Miyagawa JI, Yamamori K, et al. Ectodomain shedding of epidermal growth factor receptor ligands is required for keratinocyte migration in cutaneous wound healing. J Cell Biol. 2000; 151:209–220. [PubMed: 11038170]
- Marikovsky M, Breuing K Lui PY, Eriksson E, Higashiyama S, Farber P, et al. Appearance of heparin-binding EGF-like growth factor in wound fluid as a response to injury. Proc Natl Acad Sci USA. 1993; 90:3889–3993. [PubMed: 8483908]

x P- x P- in Value at 0.0346 at 0.0335 at 0.0130 at 0.0013 at 0.0035 at 0.0035 at 0.0035 at 0.0256 at 0.0256 at 0.0255 at 0.0255	P- Value Value 0.0346 0.0332 0.0335 0.0130 0.0256 0.0255 0.0252 0.0252		in the 6 Raw Raw 8.91 11.57 8.91 8.21 8.21 8.21 7.86 6.64 6.65 6.05 6.05 4.76 6.05 4.76 6.05 4.78 4.58 4.53 4.53 4.24 4.24 4.22	cdge of non-healing ulcers compared to the edge Gene Descriptor Un Secreted frizzled-related protein 4 Hs. Secreted frizzled-related protein 4 Hs. Collagen, type X, alpha 1 Hs. Branched chain aminotransferase 1, cytosolic Hs. Collagen, type XI, alpha 1 Hs. Sulfatase 1 Hs. Cytochrome P450, family 1, subfamily B, polypeptide 1 Hs. Cytochrome P450, family 1, subfamily B, polypeptide 1 Hs. Sulfatase 1 Cytochrome P450, family 1, subfamily B, polypeptide 1 Hs. Clusterin (complement lysis inhibitor) Hs. Hs. Clusterin (complement lysis inhibitor) Hs. Hs. Integrin, beta-like 1 (with EGF-like repeat domains) Hs. Hs. Integrin, beta-like 1 (with EGF-like repeat domains) Hs. Hs. Integrin, beta-like 1 (with EGF-like repeat domains) Hs. Hs. Integrin, beta-like 1 (with EGF-like repeat domains) Hs. Hs. Integrin, beta-like 1 (with EGF-like repeat domains) Hs. Hs. Integrin, beta-like 1 (with EGF-like repeat domains) Hs. Hs. Inthegrin, beta-like 1 (with EGF-like repeat	of healir igene ID ilo5700 ilo5700 ilo5700 ilo5700 ilo5700 ilo580 ilo54 ilo54 ilo54 ilo54 ilo58 ilo54 ilo58	g ulcers. Gene Symbol SFRP4 COL10A1 BCAT1 BCAT1 BCAT1 COL10A1 BCAT1 BCAT1 COL10A1 SULF1 CVP1B1 CVP1B1 CVP1B1 CUU CLU CLU CUU SELE HSD17B6 MOX2 SERPIAI SERPIAI SERPIAI SERPIAI SERPIAI SERPIAI SERPIAI SERPIAI SERPIAI SERPIAI SERPIAI SERPIAI SERPIAI SULF1	Sequence Derived From AW089415 AW089415 AW089415 AW089415 AL390172 BG028597 BG028597 BG028597 BG028597 AL390172 BG028597 AL390172 BG028597 AL390172 BG028597 AL479175 NM_000104.2 NM_000450.1 NM_000295 NM_001629.1 NM_001629.1 AL050262.1	Function Transcription ECM Catabolism amino acids ECM Catabolism amino acids Catabolism amino acids ECM Catabolism amino acids Catabolism amino acids Catabolism amino acids Achabolism amino acids Steroidogenesis Inflammation Cranscription Cra	Disease association Inhibition of cancer progression Schmid type metaphyseal chondrodysplasia Schmid type metaphyseal chondrodysplasia C-myc induced tumors Schmid type metaphyseal chondrodysplasia C-myc induced tumors Stickler syndrome type 2 All type of carcinoma, including SCC Breast, colon, lung, esophagus, skin, lymph node, brain, and testis cancer, congenital glaucoma Prostate cancer Tumors, vascular disease, psoriasis, Unknown Breast colon Urknown Breast cancer Urknown Breast cancer Spontaneous abortion Lung disease Stroke, asthma, MI Stroke, asthma, MI
Automatical genes in the end of the rold xn P- Raw Fold at 0.0346 11.57 at 0.0346 11.57 at 0.0345 7.86 at 0.0032 8.91 at 0.0130 6.64 at 0.0130 6.64 at 0.0130 6.64 at 0.0013 4.76 at 0.0013 4.61 at 0.0013 4.76 at 0.0055 4.53 at 0.0125 4.53 at 0.00255 4.53 at 0.00256 4.53 at 0.00255 4.22 at 0.0122 4.22 at 0.0255 4.22	Perfect genes in the diated genes in the fold Palue Raw Fold 0.0346 11.57 0.0332 8.91 0.0463 8.21 0.0463 8.21 0.0130 6.64 0.0130 6.64 0.0130 6.64 0.0130 6.64 0.0130 6.64 0.0130 6.64 0.0133 4.76 0.0013 4.61 0.0013 4.61 0.0035 4.53 0.0035 4.53 0.0035 4.53 0.0035 4.53 0.0035 4.53 0.0035 4.23 0.0035 4.23 0.0255 4.23 0.0255 4.22 0.0255 4.22 0.0255 4.22 0.0255 4.22	Answer Raw Fold 5 I1.57 5 11.57 5 8.91 5 8.91 5 7.86 5 7.86 6 6.64 1 6.05 1 6.05 1 6.05 1 6.05 1 6.05 1 6.05 1 6.05 1 6.05 1 6.05 1 6.05 1 6.05 2 4.53 3 4.76 4 4.53 5 4.53 6 4.53 7 4.24 8 4.24 1 4.22 1 4.22		dge of non-he Gene Descriptor Secreted frizzled- Collagen, type X, Branched chain a Collagen, type X Sulfatase 1 Cytochrome P45(Cytochrome P45(Cytochrome P45(Cytochrome P45(Antigen identified Runt-related trans I17-beta-hydroxisi Antigen identified Serine proteinase Arachidonate 5-li Toll-like receptor	aling ulcers compared to the edge related protein 4 Hs alpha 1 Hs minotransferase 1, cytosolic Hs minotransferase 1, cytosolic Hs (, alpha 1 Hs () family 1, subfamily B, polypeptide 1 Hs () family 1, subfamily 1, subfamily B, polypeptide 1 Hs () family 1, subfamily 1, subfam	aling ulcers compared to the edge of healir related protein 4 $Unigene ID$ related protein 4 $Hs.105700$ alpha 1 $Hs.105700$ alpha 1 $Hs.19729$ minotransferase 1, cytosolic $Hs.438933$ f. alpha 1 $Hs.134062$ f. alpha 1 $Hs.154654$ f. alpha 1 $Hs.154654$ f. family 1, subfamily B, polypeptide 1 $Hs.1954657$ f. family 1, subfamily B, polypeptide 1 $Hs.1954657$ f. hs.209746 f. hs.209746 f. hs.10557 f. hs.10194 f. hs.10194	aling ulcers compared to the edge of healing ulcers.aling ulcers compared to the edge of healing ulcers.related protein 4Unigene IDGenerelated protein 4Hs.105700SFRP4alpha 1Hs.17729COLI0A1minotransferase 1, cytosolicHs.438993BCAT1minotransferase 1, cytosolicHs.438993BCAT1minotransferase 1, cytosolicHs.438993BCAT1minotransferase 1, cytosolicHs.438993BCAT1minotransferase 1, cytosolicHs.439168COLI1A1minotransferase 1, cytosolicHs.436657CULT1minotransferase 1, cytosolicHs.439602SULF1minotransferase 1, cytosolicHs.439602SULF1minotransferase 1, cytosolicHs.436657CULT1hindity 1, subfamily B, polypeptide 1Hs.436657CULUheial adhesion molecule 1)Hs.895466SELEnent lysis inhibitor)Hs.895466SELEheial adhesion molecule 1)Hs.895466SELEotoid dehydrogenase VIHs.895466RUNX2dib monoclonal antibody MRC OX-2Hs.11958HSD17B6dib hibitor, clade A, member 1Hs.100194ALOX5APpoxygenase-activating proteinHs.111805TLR1thHs.111805TLR1	aling ulcers:aling ulcers: compared to the edge of healing ulcers:under the edge of healing ulcers: $\mathbf{Unigene ID}$ \mathbf{Gene} $\mathbf{Sequence}$ related protein 4 $\mathbf{H}_{s.179729}$ \mathbf{Gene} $\mathbf{Sequence}$ alpha 1 $\mathbf{H}_{s.179729}$ $\mathbf{RPP4}$ $\mathbf{AW089415}$ alpha 1 $\mathbf{H}_{s.179729}$ $\mathbf{RPA4}$ $\mathbf{AW089415}$ alpha 1 $\mathbf{H}_{s.19729}$ $\mathbf{H}_{s.19729}$ $\mathbf{A1376003}$ alpha 1 $\mathbf{H}_{s.19729}$ $\mathbf{H}_{s.139760}$ $\mathbf{A1376003}$ minotransferase 1, cytosolic $\mathbf{H}_{s.439168}$ $\mathbf{COL11A1}$ $\mathbf{BG028597}$ $(alpha 1)$ $\mathbf{H}_{s.439168}$ $\mathbf{COL11A1}$ $\mathbf{B1376003}$ $(alpha 1)$ $\mathbf{H}_{s.439168}$ $\mathbf{COL11A1}$ $\mathbf{A1479175}$ $(alpha 1)$ $\mathbf{H}_{s.439168}$ $\mathbf{CUL11}$ $\mathbf{A1479175}$ $(alpha 1)$ $\mathbf{H}_{s.436657}$ $\mathbf{CVP1B1}$ $\mathbf{NM_2000450.1}$ $(family 1, subfamily B, polypeptide 1\mathbf{H}_{s.154654}\mathbf{CVP1B1}\mathbf{NM_2000450.1(family 1, subfamily B, polypeptide 1\mathbf{H}_{s.331054}\mathbf{CVP1B1}\mathbf{NM_200450.1(furt EGF-like repeat domains)\mathbf{H}_{s.331054}\mathbf{CPU}\mathbf{A0469546}(furt EGF-like repeat domains)\mathbf{H}_{s.331054}\mathbf{RUNX2}\mathbf{A0469546}(furt EGF-like repeat domains)\mathbf{H}_{s.331054}\mathbf{RUNX2}\mathbf{A0469546}(furt EGF-like repeat domains)\mathbf{H}_{s.19758}\mathbf{RUNX2}\mathbf{A060591}(furt EGF-like repeat domains)\mathbf{H}_{s.19768}\mathbf{RUNX2}A0$	aling ulcers compared to the edge of healing ulcers.aling ulcers compared to the edge of healing ulcers.Unigene ID GeneRetweet Fromrelated protein 4Hs.107702Berived FromFunctionalpha 1Hs.107729SFRP4AW089415Transcriptionalpha 1Hs.179729COLI0A1A1376003ECMininotransferae L. cytosolicHs.438993BCAT1A1390172Catabolism amino acids(alpha 1Hs.179729COLI0A1BG028597ECM(alpha 1Hs.179729SULF1A1479175Hepain signaling Ca2+ binding:(alpha 1)Hs.139168COLI1A1BG028597ECM(alpha 1)Hs.154654CVT1B1NM_0001042Steroidogenesis(almily 1, subfamily B, polypeptide 1Hs.154654CVT1B1NM_0001042Steroidogenesis(funility 1, subfamily B, polypeptide 1Hs.154654CVT1B1NM_0001042Steroidogenesis(funility 1, subfamily B, polypeptide 1Hs.154654CVT1B1Ad479156Apposis(funility 1, subfamily B, polypeptide 1Hs.154654CVT1B1NM_000142Steroidogenesis(funility 1, subfamily B, polypeptide 1Hs.154654CVT1B1NM_000142Steroidogenesis(funility 1, subfamily B, polypeptide 1Hs.154654CVT1B1NM_000142Steroidogenesis(funility 1, subfamily B, polypeptide 1Hs.154654CVT1B1NM_000142Apposis(funility 1, subfamily B, polypeptide 1Hs.154654CVT1B1NM_00142Apposis(funili
x P- x P- in Value at 0.0346 at 0.0335 at 0.0346 at 0.0355 at 0.0130 at 0.0130 at 0.0130 at 0.0130 at 0.0130 at 0.0013 at 0.0013 at 0.0013 at 0.0013 at 0.00256 at 0.0035 at 0.0256 at 0.0256 at 0.0256 at 0.0256 at 0.0256 at 0.0252	lated genes P- Value Value Value 0.0346 0.0332 0.0335 0.0130 0.0130 0.0130 0.0154 0.0130 0.0130 0.0154 0.0130 0.0130 0.0154 0.0130 0.0130 0.0035 0.0035 0.0130 0.0120 0.0130 0.01256 0.0040 0.00355 0.02556 0.00255 0.02556 0.02552 0.00252 0.02552 0.02552		in the c Raw Fold Change 8.91 8.91 8.91 8.91 8.91 8.91 8.64 6.05 6.05 6.05 6.05 6.05 4.58 4.53 4.58 4.53 4.58 4.53 4.53 4.53 4.24 4.22 4.22		ge of non-healing ulcers compared to the edge tene Descriptor U ecreted frizzled-related protein 4 Hs ollagen, type X, alpha 1 Hs ranched chain aminotransferase 1, cytosolic Hs ollagen, type XI, alpha 1 Hs ranched chain aminotransferase 1, cytosolic Hs ollagen, type XI, alpha 1 Hs ulfatase 1 Hs vytochrome P450, family 1, subfamily B, polypeptide 1 Hs ultatase 1 Hs ultatase 1 Hs vochrome P450, family 1, subfamily B, polypeptide 1 Hs ultatase 1 Hs ultatase 1 Hs vochrome P450, family 1, subfamily B, polypeptide 1 Hs ultatase 1 Hs ultatase 1 Hs vochrome P450, family 1, subfamily B, polypeptide 1 Hs vochrome P450, family 1, subfamily B, polypeptide 1 Hs ultatase 1 Hs Hs vochrome P450, family 1, subfamily B, polypeptide 1 Hs ultatase 1 Hs Hs ultatase 1 Hs Unterelated transcription factor 2 Hs	ge of non-healing ulcers compared to the edge of healir eree Descriptor Unigene ID ecreted frizzled-related protein 4 Hs.105700 ecreted frizzled-related protein 4 Hs.105700 ecreted frizzled-related protein 4 Hs.43903 ranched chain aminotransferase 1, cytosolic Hs.439168 ulfatase 1 Hs.439168 ulfatase 1 Hs.439168 vochrome P450, family 1, subfamily B, polypeptide 1 Hs.439657 bytochrome P450, family 1, subfamily B, polypeptide 1 Hs.43657 ulfatase 1 Hs.430657 ulfatase 1 Hs.430657 ulfatase 1 Hs.409602 ulfatase 1 Hs.409602 ulfatase 1 Hs.409602 ulfatase 1 Hs.409602 husterin (complement lysis inhibitor) Hs.436657 electin E (endothelial adhesion molecule 1) Hs.436657 utrelated transcription factor 2 Hs.20746 utrelated transcription factor 2 Hs.509746 utrelated transcription factor 2 Hs.79015 nigen identified by monoclonal antibody MRC OX-2 Hs.79015 ricen identified by monoclonal antibody MRC OX-2 Hs.100194	ge of non-healing ulcers compared to the edge of healing ulcers.ene DescriptorUnigene IDGeneene DescriptorUnigene IDGeneecreted frizzled-related protein 4Hs.179729COLI0A1collagen, type X, alpha 1Hs.179729COLI0A1ranched chain aminotransferase 1, cytosolicHs.439168COLI1A1ollagen, type XI, alpha 1Hs.439168COLI1A1ulfatase 1Hs.439168COLI1A1ulfatase 1Hs.439168COLI1A1ulfatase 1Hs.439168COLI1A1ulfatase 1Hs.439168Kollulfatase 1Hs.439168Kollulfatase 1Hs.439168Kollulfatase 1Hs.439168Kollulfatase 1Hs.439168Kollulfatase 1Hs.439168Kollulfatase 1Hs.439168Kollulfatase 1Hs.439168Kollulfatase 1Hs.439168Kollulfatase 1Hs.1958Kollulfatase 1Hs.19567Kollulfatase 1Hs.11958Hs.D17B6ulfer identified by monoclonal antibody MRC OX-2Hs.11958HSD17B6ulfer identified by monoclonal antibody MRC OX-2Hs.100194Hs.100194ulfer identified by monoclonal antibody MRC OX-2Hs.100194AltOK5APulfer identified by monoclonal antibody MRC OX-2Hs.100194Hs.100194ulfer identified by monoclonal antibody MRC OX-2Hs.100194AltOK5APulfer identified by monoclonal antibody MRC OX-2Hs.100194AltOK5AP <td>ge of non-healing ulcers.ene DescriptorUnigene IDSquenceene DescriptorUnigene IDGeneSquenceSquenceere DescriptorHs.105700SFRP4AW089415ere de frizzled-related protein 4Hs.105700SFRP4AW089415collagen, type X, alpha 1Hs.19729COL10AIAl376003anched chain aminotransferase 1, cytosolicHs.438993BCATIAL390172ollagen, type XI, alpha 1Hs.439168COL11AIBG028597ollagen, type XI, alpha 1Hs.439168COL11AIBG028597ollagen, type XI, alpha 1Hs.439657CUUAL390172ollagen, type XI, alpha 1Hs.43667CUUAL390172ollagen, type XI, alpha 1Hs.154654CUUAl982754ulfatase 1Hs.194667Hs.134657CUUAl982754ulfatase 1Hs.134657CUUAl982754ulfatase 1Hs.134657CUUAl982754ulfatase 1Hs.1958Hs.11054INM_004501ulfatase 1Hs.19564Hs.11054NM_004501ulfatase 1Hs.196746Hs.31054MO22ulfatase 1Hs.31054Hs.20768MO20251ulfatase 1Hs.19978Hs.19788MO20251ulfatase 1Hs.100194Hs.100194NM_0016291ulfatase 1Hs.100194Hs.100194NM_0016291ulfatase 1Hs.10194Hs.100194NM_0016291ulfatase 1Hs.10194Hs.10194<td< td=""><td>Bit of non-healing ulcers compared to the edge of healing ulcers. ene bescriptor Unigene ID Symbol Gene Symbol Rueted From Intertoin erred frizzled-related protein 4 Hs.105700 SFRP4 AW089415 Transcription ollagen, type X, alpha 1 Hs.10770 SFRP4 AW089415 Transcription ollagen, type XI, alpha 1 Hs.19729 COLI0AI A1370035 ECM ollagen, type XI, alpha 1 Hs.439016 Hs.439016 Hs.439016 Stury 1 A1470175 Hepotin amino acids ollagen, type XI, alpha 1 Hs.439016 Hs.439016 Hs.439016 Hs.439016 ECM Stranscription violagenet 1 Hs.10070 Hs.439016 Hs.439016 Hs.439016 ECM Stranscription violagen Lipe XI, alpha 1 Hs.439016 Hs.439016 Hs.439016 ECM Stranscription violagen Lipe XI, alpha 1 Hs.439016 Hs.439016 Hs.439016 ECM Stranscription violagen Lipe XI, alpha 1 Hs.430016 Hs.43657 CULIAI AI479175 Hepatin signaling Ca2+ binding:</td></td<></td>	ge of non-healing ulcers.ene DescriptorUnigene IDSquenceene DescriptorUnigene IDGeneSquenceSquenceere DescriptorHs.105700SFRP4AW089415ere de frizzled-related protein 4Hs.105700SFRP4AW089415collagen, type X, alpha 1Hs.19729COL10AIAl376003anched chain aminotransferase 1, cytosolicHs.438993BCATIAL390172ollagen, type XI, alpha 1Hs.439168COL11AIBG028597ollagen, type XI, alpha 1Hs.439168COL11AIBG028597ollagen, type XI, alpha 1Hs.439657CUUAL390172ollagen, type XI, alpha 1Hs.43667CUUAL390172ollagen, type XI, alpha 1Hs.154654CUUAl982754ulfatase 1Hs.194667Hs.134657CUUAl982754ulfatase 1Hs.134657CUUAl982754ulfatase 1Hs.134657CUUAl982754ulfatase 1Hs.1958Hs.11054INM_004501ulfatase 1Hs.19564Hs.11054NM_004501ulfatase 1Hs.196746Hs.31054MO22ulfatase 1Hs.31054Hs.20768MO20251ulfatase 1Hs.19978Hs.19788MO20251ulfatase 1Hs.100194Hs.100194NM_0016291ulfatase 1Hs.100194Hs.100194NM_0016291ulfatase 1Hs.10194Hs.100194NM_0016291ulfatase 1Hs.10194Hs.10194 <td< td=""><td>Bit of non-healing ulcers compared to the edge of healing ulcers. ene bescriptor Unigene ID Symbol Gene Symbol Rueted From Intertoin erred frizzled-related protein 4 Hs.105700 SFRP4 AW089415 Transcription ollagen, type X, alpha 1 Hs.10770 SFRP4 AW089415 Transcription ollagen, type XI, alpha 1 Hs.19729 COLI0AI A1370035 ECM ollagen, type XI, alpha 1 Hs.439016 Hs.439016 Hs.439016 Stury 1 A1470175 Hepotin amino acids ollagen, type XI, alpha 1 Hs.439016 Hs.439016 Hs.439016 Hs.439016 ECM Stranscription violagenet 1 Hs.10070 Hs.439016 Hs.439016 Hs.439016 ECM Stranscription violagen Lipe XI, alpha 1 Hs.439016 Hs.439016 Hs.439016 ECM Stranscription violagen Lipe XI, alpha 1 Hs.439016 Hs.439016 Hs.439016 ECM Stranscription violagen Lipe XI, alpha 1 Hs.430016 Hs.43657 CULIAI AI479175 Hepatin signaling Ca2+ binding:</td></td<>	Bit of non-healing ulcers compared to the edge of healing ulcers. ene bescriptor Unigene ID Symbol Gene Symbol Rueted From Intertoin erred frizzled-related protein 4 Hs.105700 SFRP4 AW089415 Transcription ollagen, type X, alpha 1 Hs.10770 SFRP4 AW089415 Transcription ollagen, type XI, alpha 1 Hs.19729 COLI0AI A1370035 ECM ollagen, type XI, alpha 1 Hs.439016 Hs.439016 Hs.439016 Stury 1 A1470175 Hepotin amino acids ollagen, type XI, alpha 1 Hs.439016 Hs.439016 Hs.439016 Hs.439016 ECM Stranscription violagenet 1 Hs.10070 Hs.439016 Hs.439016 Hs.439016 ECM Stranscription violagen Lipe XI, alpha 1 Hs.439016 Hs.439016 Hs.439016 ECM Stranscription violagen Lipe XI, alpha 1 Hs.439016 Hs.439016 Hs.439016 ECM Stranscription violagen Lipe XI, alpha 1 Hs.430016 Hs.43657 CULIAI AI479175 Hepatin signaling Ca2+ binding:
x x y <thy< th=""> y y y</thy<>	ated and a second	ge g		n the e at the at the at the e at the a	a rthe edge of non-healing ulcers compared to the edge Raw Gene Descriptor U Sold Secreted frizzled-related protein 4 U 1.57 Secreted frizzled-related protein 4 Hs 8.91 Collagen, type X, alpha 1 Hs 8.21 Branched chain aminotransferase 1, cytosolic Hs 8.50 Collagen, type XI, alpha 1 Hs 5.64 Sulfatase 1 Hs 5.65 Cytochrome P450, family 1, subfamily B, polypeptide 1 Hs 5.69 Clusterin (complement lysis inhibitor) Hs 4.61 Integrin, beta-like 1 (with EGF-like repeat domains) Hs 4.61 Integrin, beta-like 1 (with EGF-like repeat domains) Hs 4.53 17-beta-hydroxisteroid dehydrogenase VI Hs 4.53 17-beta-hydroxisteroid dehydrogenases VI Hs	n the edge of non-healing ulcers compared to the edge of healination $dedge of healing ulcers compared to the edge of healinanceawsGene DescriptorUnigene ID0oldsecreted frizzled-related protein 4Hs.1057001.57Secreted frizzled-related protein 4Hs.1057001.57Secreted frizzled-related protein 4Hs.1057008.91Collagen, type X, alpha 1Hs.439938.66Collagen, type XI, alpha 1Hs.4391688.64Sulfatase 1Hs.4096025.64Sulfatase 1Hs.4366575.64Sulfatase 1Hs.4366575.64Sulfatase 1Hs.4366575.65Cytochrome P450, family 1, subfamily B, polypeptide 1Hs.4366575.69Clusterin (complement lysis inhibitor)Hs.4366575.78Runt-related transcript$	Interfaction Interfactin Interfactin I	In the edge of non-healing ulcers. aws Gene DescriptorSquence aws Gene DescriptorSequence aws Gene Descriptor ws ws ws 1.57 Secreted frizzled-related protein 4 $Hs.105700$ SFRP4 $AW089415$ 3.21 Beached frizzled-related protein 4 $Hs.105700$ SFRP4 $AW089415$ 3.21 Beached chain aminotransferase 1, cytosolic $Hs.43993$ $BCAT1$ $A1376003$ 3.21 Branched chain aminotransferase 1, cytosolic $Hs.439168$ $COL10A1$ $A1376003$ 3.21 Branched chain aminotransferase 1, cytosolic $Hs.439630$ $BCAT1$ $A139175$ 5.64 Sulfatase 1 $Hs.439602$ $SULF1$ $A1479175$ 5.64 Sulfatase 1 $Hs.439667$ $CUL1A1$ $BG0283797$ 5.64 Sulfatase 1 $Hs.439667$ $CUL1A1$ $BG028374$ 5.657 Cytochrome P450, family 1, subfamily B, polypeptide 1 $Hs.154654$ $CTU1$ $A137603$ 5.69 Cytochrome P450, family 1, subfamily B, polypeptide 1 $Hs.154654$ $CTU1$ $A1379175$ 5.64 Sulfatase 1 $Hs.19667$ $Hs.19667$ $Mu_0004501$ 5.64 Sulfatase 1 $Hs.196676$ $Hs.19676$ $Hs.19676$ 5.67 Invertine techorel 1) $Hs.311054$ $Hs.20768$ Mu_004501 5.78 $Hun-related transcription factor 2Hs.3006746Hs.20766Hs.00026545.78Hun-related transcription$	In the edge of non-healing ulcers:In the edge of non-healing ulcers compared to the edge of healing ulcers; $\frac{600}{6000}$ $\frac{600}{60000}$ $\frac{60000}{80000000000000000000000000000000$
ang at at at at at a at a at a a at a	$\overrightarrow{\mathbf{H}} = \left\{ \begin{array}{c} \mathbf{H} \\ \mathbf{H} \end{array} \right\} \left\{ \begin{array}{c} \mathbf{H} \\ \mathbf{H} \end{array}\right\} \left\{ \begin{array}{c} \mathbf{H} \\ \mathbf{H} \end{array} \right\} \left\{ \begin{array}{c} \mathbf{H} \\ \mathbf{H} \end{array} \right\} \left\{ \begin{array}{c} \mathbf{H} \\ \mathbf{H} \end{array} \right\} \left\{ \begin{array}{c} \mathbf{H} \\ \mathbf{H} \end{array}\right\} \left\{ \begin{array}{c} \mathbf{H} \\ \mathbf{H} \end{array} \right\} \left\{ \left\{ \mathbf{H} \\ \mathbf{H} \end{array}\right\} \left\{ \left\{ \mathbf{H} \\ \mathbf{H} \end{array} \right\} \left\{ \left\{ \mathbf{H} \\ H$	ated ge Value 0.0035 0.0046 0.0046 0.0046 0.0046 0.0046 0.0015 0.0015 0.0015 0.0015 0.0015 0.0005 0.00035 0.0005 0.00035 0.00035 0.0005 00005 00005 00000000		res in the e	Raw Gene Descriptor U Fold Change Gene Descriptor U Fold Secreted frizzled-related protein 4 Hs 11.57 Secreted frizzled-related protein 4 Hs 8:91 Collagen, type X, alpha 1 Hs 8:21 Branched chain aminotransferase 1, cytosolic Hs 7.86 Collagen, type XI, alpha 1 Hs 6.64 Sulfatase 1 Hs 6.64 Sulfatase 1 Hs 6.65 Cytochrome P450, family 1, subfamily B, polypeptide 1 Hs 6.05 Cytochrome P450, family 1, subfamily B, polypeptide 1 Hs 6.05 Cytochrome P450, family 1, subfamily B, polypeptide 1 Hs 6.05 Cytochrome P450, family 1, subfamily B, polypeptide 1 Hs 6.05 Cytochrome P450, family 1, subfamily B, polypeptide 1 Hs 6.05 Cytochrome P450, family 1, subfamily B, polypeptide 1 Hs 6.05 Cytochrome P450, family 1, subfamily B, polypeptide 1 Hs 6.05 Cytochrome P450, family 1, subfamily B, polypeptide 1 Hs 6.06 Selectin E (endothelial adhesion molecule 1) Hs	Raw Gene Descriptor Unigene ID Raw Gene Descriptor Unigene ID Fold 8.91 Collagen, type X, alpha 1 Hs, 105700 8.91 Collagen, type XI, alpha 1 Hs, 438903 7.86 Collagen, type XI, alpha 1 Hs, 439168 7.86 Collagen, type XI, alpha 1 Hs, 439168 6.64 Sulfatase 1 Hs, 409602 6.65 Cytochrome P450, family 1, subfamily B, polypeptide 1 Hs, 409602 6.05 Cytochrome P450, family 1, subfamily B, polypeptide 1 Hs, 436657 6.05 Cytochrome P450, family 1, subfamily B, polypeptide 1 Hs, 436657 6.05 Cytochrome P450, family 1, subfamily B, polypeptide 1 Hs, 436657 6.05 Cytochrome P450, family 1, subfamily B, polypeptide 1 Hs, 436657 6.05 Cytochrome P450, family 1, subfamily B, polypeptide 1 Hs, 436657 6.05 Cytochrome P450, family 1, subfamily B, polypeptide 1 Hs, 436657 6.05 Cytochrome P450, family 1, subfamily B, polypeptide 1 Hs, 436657 6.05 Cytochrome P450, family 1, subfamily B, polypeptide 1 Hs, 436657 6.05 Cytochrom P450, family 1	Raw Gene Descriptor Unigen CI healing ulcers. Raw Fold Gene Descriptor Unigen ID Gene Fold 8.91 Collagen, type X, alpha 1 Hs.179729 CULI0A1 8.91 Collagen, type X, alpha 1 Hs.179729 CULI0A1 8.91 Collagen, type X, alpha 1 Hs.438993 BCAT1 7.86 Collagen, type XI, alpha 1 Hs.438993 BCAT1 7.81 Sulfatase 1 Hs.438993 BCAT1 6.64 Sulfatase 1 Hs.438993 BCAT1 6.65 Cytochrone P450, family 1, subfamily B, polypeptide 1 Hs.438657 CUL1A1 6.05 Cytochrone P450, family 1, subfamily B, polypeptide 1 Hs.154654 CTU 6.05 Cytochrone P450, family 1, subfamily B, polypeptide 1 Hs.438657 CLU 6.05 Cytochrone P450, family 1, subfamily B, polypeptide 1 Hs.436657 CLU 6.05 Cytochrone P450, family 1, subfamily B, polypeptide 1 Hs.436657 CLU 6.05 Cytochrone P450, family 1, subfamily B, polypeptide 1 Hs.436657 CLU 6.05 Cytochrone P450, family 1, subfamily B, polypeptide 1 Hs.436657 CLU	Ray for edge of non-healing ulcers compared to the edge of healing ulcers.Ray Foud Foud ChangeGene DescriptorUnigen LDSequence Symbol11.57Secreted frizhed-related protein 4Hs.179729COLIIA1Al3760038.91Collagen, type X, alpha 1Hs.179729COLIIA1Al3760038.21Branched chain aminotransferase 1, cytosolicHs.438993BCAT1Al391727.86Collagen, type X1, alpha 1Hs.439168COLIIA1BG0285976.64Sulfatase 1Hs.409602SULF1Al4991756.65Cytochrone P450, family 1, subfamily B, polypeptide 1Hs.154654CVIIIA1BG0285976.67Usterin (complement lysis inhibitor)Hs.439667CLUAl9827546.68Cytochrone P450, family 1, subfamily B, polypeptide 1Hs.154654SELENM_00045017.86Cytochrone P450, family 1, subfamily B, polypeptide 1Hs.154654SELENM_00045016.69Cytochrone P450, family 1, subfamily B, polypeptide 1Hs.154654SELENM_00045016.61Sulfatase 1Hs.109506Hs.311054Hs.31054Mo045017.86Integrin, beta-like 1 (with EGF-like repeat domains)Hs.311054Hs.31054Mo4695467.81Integrin, beta-like 1 (with EGF-like repeat domains)Hs.311054Hs.211766NM_4695467.82Integrin, beta-like 1 (with EGF-like repeat domains)Hs.31054Hs.211766NM_4695467.83Integrin, beta-like 1 (with EGF-like repeat domains)Hs.31054Hs.	Any of the edge of healing ulcers. Index of the edge of non-healing ulcers. Raw Fere bescriptor Unigene ID Squeme Function 11.57 Scened frizzbel-related protein 4 Hx10570 StrPA4 AW089415 Transcription 82.91 Collagen, type X, alpha 1 Hx17972 COLIANI A1570035 ECM 82.02 Collagen, type X, alpha 1 Hx17972 COLIANI B007055 ECM 82.01 Secreted frizzbel-related protein 4 Hx17975 Kubol05 ECM 82.01 Branched chain aminotransferase 1, cytosolic Hx439165 COLIANI B479755 Chaboling maino acids 82.01 Selectin E Collagen, type X, alpha 1 Hx439165 BCATI A1391755 Hepoting anding: 66.05 Cytochrone P450, framity 1, subfamily B, polypeptide 1 Hx15454 CYTBI B4000104.2 Steroidogenesis 66.05 Cytochrone P450, framity 1, subfamily B, polypeptide 1 Hx154554 CYTBI B4000104.2 Steroidogenesis 67.05 Cytochrone P450, framity 1, subfamily B, polypeptide 1
		gulated gulated <t< td=""><td>ger 1</td><td>genes in the e Raw e Raw 11.57 346 332 8.91 333 8.21 335 7.86 335 7.86 330 6.64 313 6.64 313 4.76 313 4.61 313 4.61 313 4.61 313 4.61 313 4.61 313 4.61 313 4.61 313 4.61 313 4.61 313 4.61 313 4.61 313 4.61 314 4.61 315 4.53 315 4.53 315 4.24 325 4.22 325 4.22</td><td>Between the edge of non-healing ulcers compared to the edge of 11.57 Secreted frizzled-related protein 4 Undefine 332 8.91 Collagen, type X, alpha 1 Hs 333 7.86 Collagen, type X, alpha 1 Hs 333 7.86 Collagen, type XI, alpha 1 Hs 330 6.64 Sulfatase 1 Hs 331 6.64 Sulfatase 1 Hs 333 7.86 Collagen, type XI, alpha 1 Hs 330 6.64 Sulfatase 1 Hs 331 6.64 Sulfatase 1 Hs 333 7.86 Cytochrome P450, family 1, subfamily B, polypeptide 1 Hs 334 4.76 Selectin E (endothelial adhesion molecule 1) Hs 34 5.99 Clusterin (complement 1ysis inhibitor) Hs 35 4.76 Selectin E (endothelial adhesion molecule 1) Hs 364 4.61 Integrin, beta-like 1 (with EGF-like repeat domains) Hs 375 4.76 Selectin E (endothelial adhesion molecule 1) Hs 3</td><td>Bene in the edge of non-healing ulcers compared to the edge of healinueRawGene DescriptorUnigene ID44611.57Secreted frizzled-related protein 4Hs.105700328.91Collagen, type X, alpha 1Hs.1797294638.21Branched chain aminotransferase 1, cytosolicHs.4391684757.86Collagen, type XI, alpha 1Hs.4391684806.64Sulfatase 1Hs.4096024816.05Cytochrome P450, family 1, subfamily B, polypeptide 1Hs.4391684837.86Collagen, type XI, alpha 1Hs.4391684845.99Clusterin (complement lysis inhibitor)Hs.4391684845.99Clusterin (complement lysis inhibitor)Hs.4391684855.99Clusterin (complement lysis inhibitor)Hs.4306574864.58Runt-related transcription factor 2Hs.4306574864.58Runt-related transcription factor 2Hs.4306574934.76Selectin E (endothelial adhesion molecule 1)Hs.4306574944.5317-beta-hydroxisteroid dehydrogenase VIHs.4306574954.58Runt-related transcription factor 2Hs.4301584954.5317-beta-hydroxisteroid dehydrogenase VIHs.4119584954.53Antigen identified by monoclonal antibody MRC OX-2Hs.790154954.24Serine proteinase inhibitor, clade A, member 1Hs.1001944954.22Arachidonate 5-lipoxygenase-activating proteinHs.111805495<</td><td>gene of non-healing ulcers compared to the edge of healing ulcers.RawGene DescriptorUnigene IDSymbol$46$$11.57$Secreted frizzled-related protein $4$$Hs.105700$SFRP4$332$$8.91$Collagen, type X, alpha 1$Hs.105700$SFRP4$332$$8.91$Collagen, type X, alpha 1$Hs.179729$COLI0A1$333$$7.86$Collagen, type XI, alpha 1$Hs.179729$COLI0A1$330$$6.64$Sulfatase 1$Hs.439168$COLI1A1$330$$6.64$Sulfatase 1$Hs.439168$COLI0A1$340$Collagen, type XI, alpha 1$Hs.439168$COLI1A1$300$$6.64$Sulfatase 1$Hs.439168$COLI1A1$310$$6.64$Sulfatase 1$Hs.439168$COLI1A1$310$$6.64$Sulfatase 1$Hs.439168$COLI1A1$310$$6.64$Sulfatase 1$Hs.439168$COLI1A1$310$$6.64$Sulfatase 1$Hs.439168$COLI1A1$310$$6.64$Sulfatase 1$Hs.439168$COLI1A1$310$$6.64$Sulfatase 1$Hs.439657$$CUU$$311$$4.76$Selectin E (endothelial adhsion molecule 1)$Hs.331054$$CVI$$311$$4.76$Selectin E (endothelial adhsion molecule 1)$Hs.331054$$Hs.31054$$311$$Hs.31054$$Hs.436657$$Hs.31054$$Hs.31054$$312$$4.58$<math>Hun-related transcription factor 2$Hs.30768$$Hs.30768$$3$</math></td><td>Believed in the edge of healing ulcers.RawGene DescriptorueRawGene DescriptorUnigene IDSymbolBerived From4611.57Secreted frizzled-related protein 4Hs.105700SFRP4AM0894154611.57Secreted frizzled-related protein 4Hs.107709SOLI.0A1Al3760034611.57Secreted frizzled-related protein 4Hs.179729COLI.0A1Al37600347Soll geen, type X, alpha 1Hs.179729COLI.0A1Al37600348S.11Branched chain aminotransferase 1, cytosolicHs.438903BCAT1BG02859749Collagen, type X, alpha 1Hs.439168COLI.1A1BG028597406.64Sulfatase 1Hs.499605SULF1Al479175406.64Sulfatase 1Hs.154654CUL1A1BG028597406.64Sulfatase 1Hs.154654CUL1A1BG028591415.99Clusterin (complement lysis inhibitor)Hs.154654CUL1A1Al982754415.99Clusterin (complement lysis inhibitor)Hs.354654CUL1A1Al982754415.99Clusterin (complement lysis inhibitor)Hs.436657CULAl982754415.99Clusterin (complement lysis inhibitor)Hs.31054CUL1A1Nu.001042411.47Selectin E (endothedial adhesion nolecule 1)Hs.346657CULAl469546411.47Selectin E (endothedial adhesion nolecule 1)Hs.31054</td></t<> <td>gene of non-healing ulcers.Reg of non-healing ulcers compared to the edg of healing ulcers.<math>reRayGene DescriptorUnigene IDSymbolRepenseInterconsection<math>reFundsSecreted frizzled-related protein 4Hs.19752Col.Jub.1Al376003Fundso<math>reSolgene UpSecreted frizzled-related protein 4Hs.19752COLJub.1Al376003ECM<math>reSolgene, type X. alpha 1Hs.19752COLJub.1Al376003ECM<math>reSolgene, type X. alpha 1Hs.438093BCAT1Al376003ECM<math>reSolgene, type X. alpha 1Hs.43906COLJub.1Bio0722Collagene type XI.<math>reSolgene, type XI. alpha 1Hs.439063COLJub.1Bio0723CHAP1<math>reSolfene PLS0, family 1, subhamily B, polypeptide 1Hs.1479175Hepoin Signaling Ca2+ binding:<math>reSolfCytochrome PLS0, family 1, subhamily B, polypeptide 1Hs.1479175Al479175Retroin Signaling Ca2+<math>reSolfCytochrome PLS0, family 1, subhamily B, polypeptide 1Hs.1479175Al479175Retroin Signaling Ca2+<math>reSolfCytochrome PLS0, family 1, subhamily B, polypeptide 1Hs.1476175Al479175Retroin Signaling Ca2+<math>reSolfCytochrome PLS0, family 1, subhamily B, polypeptide 1Hs.1479175Al479175Retroin Signaling Ca2+<math>reSolfCytochrome PLS0, family 1, subhamily B, polypeptide 1Hs.1479175Al479175Al479175$reSolfCytochr$</math></math></math></math></math></math></math></math></math></math></math></math></math></td>	ger 1	genes in the e Raw e Raw 11.57 346 332 8.91 333 8.21 335 7.86 335 7.86 330 6.64 313 6.64 313 4.76 313 4.61 313 4.61 313 4.61 313 4.61 313 4.61 313 4.61 313 4.61 313 4.61 313 4.61 313 4.61 313 4.61 313 4.61 314 4.61 315 4.53 315 4.53 315 4.24 325 4.22 325 4.22	Between the edge of non-healing ulcers compared to the edge of 11.57 Secreted frizzled-related protein 4 Undefine 332 8.91 Collagen, type X, alpha 1 Hs 333 7.86 Collagen, type X, alpha 1 Hs 333 7.86 Collagen, type XI, alpha 1 Hs 330 6.64 Sulfatase 1 Hs 331 6.64 Sulfatase 1 Hs 333 7.86 Collagen, type XI, alpha 1 Hs 330 6.64 Sulfatase 1 Hs 331 6.64 Sulfatase 1 Hs 333 7.86 Cytochrome P450, family 1, subfamily B, polypeptide 1 Hs 334 4.76 Selectin E (endothelial adhesion molecule 1) Hs 34 5.99 Clusterin (complement 1ysis inhibitor) Hs 35 4.76 Selectin E (endothelial adhesion molecule 1) Hs 364 4.61 Integrin, beta-like 1 (with EGF-like repeat domains) Hs 375 4.76 Selectin E (endothelial adhesion molecule 1) Hs 3	Bene in the edge of non-healing ulcers compared to the edge of healinueRawGene DescriptorUnigene ID44611.57Secreted frizzled-related protein 4Hs.105700328.91Collagen, type X, alpha 1Hs.1797294638.21Branched chain aminotransferase 1, cytosolicHs.4391684757.86Collagen, type XI, alpha 1Hs.4391684806.64Sulfatase 1Hs.4096024816.05Cytochrome P450, family 1, subfamily B, polypeptide 1Hs.4391684837.86Collagen, type XI, alpha 1Hs.4391684845.99Clusterin (complement lysis inhibitor)Hs.4391684845.99Clusterin (complement lysis inhibitor)Hs.4391684855.99Clusterin (complement lysis inhibitor)Hs.4306574864.58Runt-related transcription factor 2Hs.4306574864.58Runt-related transcription factor 2Hs.4306574934.76Selectin E (endothelial adhesion molecule 1)Hs.4306574944.5317-beta-hydroxisteroid dehydrogenase VIHs.4306574954.58Runt-related transcription factor 2Hs.4301584954.5317-beta-hydroxisteroid dehydrogenase VIHs.4119584954.53Antigen identified by monoclonal antibody MRC OX-2Hs.790154954.24Serine proteinase inhibitor, clade A, member 1Hs.1001944954.22Arachidonate 5-lipoxygenase-activating proteinHs.111805495<	gene of non-healing ulcers compared to the edge of healing ulcers.RawGene DescriptorUnigene IDSymbol 46 11.57 Secreted frizzled-related protein 4 $Hs.105700$ SFRP4 332 8.91 Collagen, type X, alpha 1 $Hs.105700$ SFRP4 332 8.91 Collagen, type X, alpha 1 $Hs.179729$ COLI0A1 333 7.86 Collagen, type XI, alpha 1 $Hs.179729$ COLI0A1 330 6.64 Sulfatase 1 $Hs.439168$ COLI1A1 330 6.64 Sulfatase 1 $Hs.439168$ COLI0A1 340 Collagen, type XI, alpha 1 $Hs.439168$ COLI1A1 300 6.64 Sulfatase 1 $Hs.439168$ COLI1A1 310 6.64 Sulfatase 1 $Hs.439657$ CUU 311 4.76 Selectin E (endothelial adhsion molecule 1) $Hs.331054$ CVI 311 4.76 Selectin E (endothelial adhsion molecule 1) $Hs.331054$ $Hs.31054$ 311 $Hs.31054$ $Hs.436657$ $Hs.31054$ $Hs.31054$ 312 4.58 $Hun-related transcription factor 2Hs.30768Hs.307683$	Believed in the edge of healing ulcers.RawGene DescriptorueRawGene DescriptorUnigene IDSymbolBerived From4611.57Secreted frizzled-related protein 4Hs.105700SFRP4AM0894154611.57Secreted frizzled-related protein 4Hs.107709SOLI.0A1Al3760034611.57Secreted frizzled-related protein 4Hs.179729COLI.0A1Al37600347Soll geen, type X, alpha 1Hs.179729COLI.0A1Al37600348S.11Branched chain aminotransferase 1, cytosolicHs.438903BCAT1BG02859749Collagen, type X, alpha 1Hs.439168COLI.1A1BG028597406.64Sulfatase 1Hs.499605SULF1Al479175406.64Sulfatase 1Hs.154654CUL1A1BG028597406.64Sulfatase 1Hs.154654CUL1A1BG028591415.99Clusterin (complement lysis inhibitor)Hs.154654CUL1A1Al982754415.99Clusterin (complement lysis inhibitor)Hs.354654CUL1A1Al982754415.99Clusterin (complement lysis inhibitor)Hs.436657CULAl982754415.99Clusterin (complement lysis inhibitor)Hs.31054CUL1A1Nu.001042411.47Selectin E (endothedial adhesion nolecule 1)Hs.346657CULAl469546411.47Selectin E (endothedial adhesion nolecule 1)Hs.31054	gene of non-healing ulcers.Reg of non-healing ulcers compared to the edg of healing ulcers. $reRayGene DescriptorUnigene IDSymbolRepenseInterconsectionreFundsSecreted frizzled-related protein 4Hs.19752Col.Jub.1Al376003FundsoreSolgene UpSecreted frizzled-related protein 4Hs.19752COLJub.1Al376003ECMreSolgene, type X. alpha 1Hs.19752COLJub.1Al376003ECMreSolgene, type X. alpha 1Hs.438093BCAT1Al376003ECMreSolgene, type X. alpha 1Hs.43906COLJub.1Bio0722Collagene type XI.reSolgene, type XI. alpha 1Hs.439063COLJub.1Bio0723CHAP1reSolfene PLS0, family 1, subhamily B, polypeptide 1Hs.1479175Hepoin Signaling Ca2+ binding:reSolfCytochrome PLS0, family 1, subhamily B, polypeptide 1Hs.1479175Al479175Retroin Signaling Ca2+reSolfCytochrome PLS0, family 1, subhamily B, polypeptide 1Hs.1479175Al479175Retroin Signaling Ca2+reSolfCytochrome PLS0, family 1, subhamily B, polypeptide 1Hs.1476175Al479175Retroin Signaling Ca2+reSolfCytochrome PLS0, family 1, subhamily B, polypeptide 1Hs.1479175Al479175Retroin Signaling Ca2+reSolfCytochrome PLS0, family 1, subhamily B, polypeptide 1Hs.1479175Al479175Al479175reSolfCytochr$
up- reg fymetri obe Set 6517_at 6517_at 6517_at 2235_at 2235_at 22437_s_ 22437_s_ 22437_s_ 22437_s_ 22437_s_ 22833_s_ 5859_at 512_at 512_at 1174_att 1174_att	up- regu fymetrix obe Set II 4051_s_at 6517_at 9271_x_at 2353_at 2353_at 2437_s_at 2437_s_at 5422_s_at 5859_at 5859_at 5859_at 5859_at 5859_at 1174_at 1174_at		P P Value 0.0346 0.0346 0.0346 0.0336 0.0130 0.0154 0.0154 0.0154 0.0156 0.0156 0.01256 0.00355 0.00356 0.00357 0.00356 0.00357 0.00356 0.00357	P- Raw Value P- Raw Fold 0.0346 11.57 0.0032 8.91 0.0463 8.21 0.0463 8.21 0.0130 6.64 0.0130 6.64 0.0130 6.64 0.0154 5.99 0.0154 5.99 0.0190 4.61 0.0155 4.53 0.0035 4.53 0.0035 4.53 0.0035 4.53 0.0035 4.53 0.0035 4.53 0.0035 4.53 0.0035 4.53 0.0035 4.53 0.0035 4.53 0.0035 4.53 0.0035 4.53 0.0035 4.53 0.0040 4.38 0.00255 4.24 0.0122 4.22 0.0255 4.22	Idated genes in the edge of non-healing ulcers compared to the edgeP.Raw Fold ChangeGene DescriptorU1 2 $Value$ Raw Fold ChangeGene Descriptor 11.57 3 0.0346 11.57 Secreted frizzled-related protein 4 Hs 0.0032 8.91 Collagen, type XI, alpha 1 Hs 1 0.0235 7.86 Collagen, type XI, alpha 1 Hs 1 0.0235 7.86 Collagen, type XI, alpha 1 Hs 0.0130 6.64 Sulfatase 1 Hs 0.0130 6.64 Sulfatase 1 Hs 0.0154 5.99 Crytochrome P450, family 1, subfamily B, polypeptide 1 Hs 0.0154 5.99 Clusterin (complement lysis inhibitor) Hs 0.0156 4.58 Runt-related transcription factor 2 Hs 0.0013 4.76 Selectin E (endothelial adhesion molecule 1) Hs 0.0013 4.61 Integrin, beta-lydroxisteroid dehydrogenase VI Hs 0.00256 4.53 17 -beta-hydroxisteroid dehydrogenase VI Hs 0.0040 4.38 Antigen identified by monoclonal antibody MRC OX-2 Hs 0.0022 4.24 Serine proteinase inhibitor, clade A, member 1 Hs 0.00222 4.22	Ideade of non-healing ulcers compared to the edge of healinP.Raw FoldGene DescriptorUnigene ID \circ ValueRaw FoldGene DescriptorHs.105700 \circ 0.034611.57Secreted frizzled-related protein 4Hs.105700 \circ 0.00328.91Collagen, type X, alpha 1Hs.438953 \circ 0.00337.86Collagen, type XI, alpha 1Hs.439168 \circ 0.01306.64Sulfatase 1Hs.439168 \circ 0.01306.64Sulfatase 1Hs.439168 \circ 0.01316.05Cytochrome P450, family 1, subfamily B, polypeptide 1Hs.4396657 \circ 0.01545.99Clusterin (complement lysis inhibitor)Hs.436657 \circ 0.01545.99Clusterin (complement lysis inhibitor)Hs.436657 \circ 0.01334.76Selectin E (endothelial adhesion molecule 1)Hs.89546 \circ 0.01334.5317-beta-like 1 (with EGF-like repeat domains)Hs.11958 \circ 0.01354.5317-beta-like 1 (with EGF-like repeat domains)Hs.10958 \circ 0.00354.5317-beta-like 1 (with EGF-like repeat domains)Hs.11958 \circ 0.00354.5317-beta-like 1 (with EGF-like repeat domains)Hs.10958 \circ 0.002354.5317-beta-like 1 withitor, clade A, member 1Hs.10958 \circ 0.002324.24Serine proteinase inhibitor, clade A, member 1Hs.100194 \circ 0.02224.22Andigen identified by monoclonal antibody MRC 0X-2Hs.101954 \circ 0.02224.22Andieneified endoteinase inhibitor, clade A, memb	Indeeding of non-healing ulcers compared to the edge of healing ulcers. P_{rold} R_{rold} C_{longe} D_{rolgen}	Interedie of non-healing ulcers compared to the edge of healing ulcers. Partie Raw Gene Descriptor Symbol Berived From 0.0034 11.57 Secreted frizzled-related protein 4 Hs.179729 COLI0A1 AM089415 0.0035 8.91 Collagen, type X, alpha 1 Hs.179729 COLI0A1 AI376003 0.0035 8.91 Collagen, type X, alpha 1 Hs.179729 COLI0A1 AI37603 0.0035 8.91 Collagen, type X, alpha 1 Hs.179729 COLI0A1 AI37603 0.0035 8.91 Collagen, type X, alpha 1 Hs.19729 COLI0A1 AI37603 0.0035 8.91 Collagen, type X, alpha 1 Hs.19759 AU409602 AI479175 0.0130 6.64 Sulfatase 1 Hs.439667 CULI0A1 AI479175 0.0130 6.64 Sulfatase 1 Hs.439667 CULI0A1 AI479175 0.0131 6.64 Sulfatase 1 Hs.439667 CULI0A1 AI479175 0.0132 6.64 Sulfatase 1 Hs.149602 SULF1	Inter edge of non-healing ulcers. P Rever from Constant of the edge of healing ulcers. P Found Expendence Expendence Expendence Expendence Expendence 0 0.346 11.57 Secreted frizzket-related protein 4 Hs.105700 SFRP4 AW089415 Function 0 0.316 11.57 Secreted frizzket-related protein 4 Hs.10750 Secreted From Reved From 0 0.315 8.01 Colageon, type X.1 alpha 1 Hs.13750 COLIJA1 BG07355 ECM 0 0.325 7.86 Colageon, type X.1 alpha 1 Hs.137603 ECM Transcription 0 0.32 7.86 Colageon, type X.1 alpha 1 Hs.137603 ECM Alf39175 0 0.32 7.86 Colageon, type X.1 alpha 1 Hs.137603 ECM Alf39175 0 0.316 6.47 Alf3916 ECM Alf39175 Headendence 0 0.316 6.45 CULIA Hs.135603

Table 1

Author Manuscript

Charles et al.

Table 2

Top15 down- regulated genes in the edge of non-healing ulcers compared to the edge of healing ulcers.

Affymetrix P-Value Raw Fold Change Gene Descriptor Un	P-Value Raw Fold Change Gene Descriptor Un	Raw Fold Change Gene Descriptor Un	Gene Descriptor Un	۵, I	uigene ID	Gene Symbol	Sequence Derived From	Function	Disease association
Probe Set	0	0	4		D				
209800_at 0.0013 -258.78 Keratin 16 (focal non- epidermolytic palmoplantar keratoderma)	0.0013 –258.78 Keratin 16 (focal non- epidermolytic palmoplantar keratoderma)	–258.78 Keratin 16 (focal non- epidermolytic palmoplantar keratoderma)	Keratin 16 (focal non- epidermolytic palmoplantar keratoderma)		Hs.432448	KRT16	AF061812.1	Cytoskeleton; structural integrity of epithelial cell	Pachyonychia congenita typ 1; nonepidermolytic palmoplantar keratoderma;metaplasias; carcinomas of the uterine cervix; psoriasis vulgaris
205064_at 0.0018 -153.18 Small proline- rich protein 1B (cornifin) (cornifin)	0.0018 –1.53.18 Small proline- rich protein 1B (cornifin)	-153.18 Small proline- rich protein 1B (cornifin)	Small proline- rich protein 1B (cornifin)		Hs.1076	SPRR1B	NM_003125.1	Cornified envelope formation	Biomarker for squamous metaplasia in eye
215704_at 0.0030 -150.44 Filaggrin	0.0030 –150.44 Filaggrin	-150.44 Filaggrin	Filaggrin		Hs.73995	FLG	AL356504	Terminal keratinocyte differentiation	Ichthyosis vulgaris;atopic eczema; atopic dermatitis;
41469_at 0.0014 -126.11 Protease inhibitor 3, skin- derived inhibitor 3, skin- derived	0.0014 –126.11 Protease inhibitor 3, skin- derived (SKALP)	-126.11 Protease inhibitor 3, skin- derived (SKALP)	Protease inhibitor 3, skin- derived (SKALP)	-	Hs.112341	PI3	L10343	An antiproteinase; elastase inhibitor	Psoriasis; squamous cell carcinoma of the lung
205916_at 0.0017 -120.44 \$\$100 calcium F binding protein A7 (psoriasin 1) A7 (psoriasin 1) B100 (psorias	0.0017 -120.44 S100 calcium F binding protein A7 (psoriasin 1)	-120.44 S100 calcium F binding protein A7 (psoriasin 1)	S100 calcium binding protein A7 (psoriasin 1)	Ξ.	Is.112408	S100A7	NM_002963.2	Chemotactic inflammatory protein for CD4+ T lymphocytes and neutrophils	Psoriasis; breast cancer progression
226926_at 0.0002 –96.77 Dermokine F	0.0002 –96.77 Dermokine F	-96.77 Dermokine F	Dermokine	Т	Is.417795	DMKN	AA706316	Epidermal morphogenesis	Inflammatory diseases
212236_x_at 0.0033 -94.47 Keratin 17 H	0.0033 –94.47 Keratin 17 H	-94.47 Keratin 17 H	Keratin 17 H	Н	s.2785	KRT17	Z19574	Cytoskeleton; structural integrity of epithelial cell	Pachyonychia congenita type 2; steatocystoma multiplex; psoriasis
266_s_at 0.0000 -64.13 CD24 antigen F (small cell lung carcinoma carcinoma cluster 4 antigen)	0.0000 –64.13 CD24 antigen F (small cell lung carcinoma curcinoma cluster 4 antigen)	-64.13 CD24 antigen F (small cell lung carcinoma cluster 4 antigen)	CD24 antigen (small cell lung carcinoma cluster 4 antigen)	н	ls.375108	CD24	L33930	Modulates b-cell activation; embryonic vasculogenesis	Wound healing
209125_at 0.0051 -61.50 Keratin 6A	0.0051 –61.50 Keratin 6A	-61.50 Keratin 6A	Keratin 6A		Hs.367762	KR76A	J00269.1	Cytoskeleton; structural integrity of epithelial cell	Pachyonychia congenita type 1 nonepidermolytic palmoplantar keratoderma;metaplasias; carcinomas of the uterine cervix;psoriasis vulgaris
33323_r_at 0.001957.40 stratifin	0.0019 –57.40 stratifin	-57.40 stratifin	stratifin		Hs.184510	SFN	X57348	Adapter protein: p53-regulated inhibitor of g2/m progression	Squamous cell carcinoma, melanoma progression; breas ovarian and pancreatic cancer progression
200606_at 0.0018 -54.62 Desmoplakin	0.0018 –54.62 Desmoplakin	–54.62 Desmoplakin	Desmoplakin		Hs.349499	DSP	NM_004415.1	Component of functional desmosomes	Cardiomyopathy; acantholyti epidermolysis bullosa;

_ ``
- `` +
~
~
5
- =
2
0
-
~
<u> </u>
Щ
an
anu
anus
anuso
anusci
anuscri
anuscrip
anuscript

Т

٦

Г

Disease association	keratoderma, blisters, nail dystrophy	corneal edema, renal disease	Epidermolysis bullosa simplex, Dowling-Meara, Weber-Cockayne type and Koebner type	Pachyonychia congenita type 2	Acute promyelocytic leukemia
Function		A water channel protein	Cyroskeleton; structural integrity of epithelial cell	Cytoskeleton; structural integrity of epithelial cell	Anticoagulant, inhibitor of the thromboplastin-specific complex
Sequence Derived From		N74607	BC002690.1	AI831452	NM_001630.1
Gene Symbol		AQP3	KRT14	KRT6B	ANXA8
Unigene ID		Hs.234642	Hs.355214	Hs.432677	Hs.87268
Gene Descriptor		Aquaporin 3	Keratin 14	Keratin 6B	Annexin A8
Raw Fold Change		-48.01	-46.13	-43.98	-43.75
P-Value		0.0078	0.0068	0.0081	0.0040
Affymetrix Probe Set ID		39248_at	209351_at	213680_at	203074_at
		12	13	14	15

Author	
Manuscript	

Table 3

Ś	
5	
ŭ	
Ц	
5	
.⊟	
-Te	
ö	
Ē,	
ч	
0	
-	
ŏ	
р.	
e)	
Ĕ.	
ن ه:	
0	
ğ	
<u> </u>	
a	
þ	
В	
5	
õ	
S	
8	
8	
Ĕ	
60	
n	
Ξ	
g	
ъ	
<u></u>	
u	
2	
F	
f	
0	
q	
_ e	
ى.	
ē	
Ę.	
Ξ	
H	
S	
Ö	
E.	
- e	
00	
ğ	
E	
g	
Е	
50	
ē	
Ч	
Ļ	
甘	
Ś	
-	
þ	
, O'	
L	

Disease association	Rheumatoid arthritis, atherosclerosis		Myocardial infarction, keloids	Glyoblastoma and neruoblastoma	Breast, colon, lung, esophagus, skin, lymph node, brain, and testis cancer, congenital glaucoma	Atherosclerosis, hypertrigly ceridemia, insulin resistance	Glucocorticoid resistance; prostate cancer; idiopathic myelofibrosis	Breast and ovarian cancer	Wound healing, skin cancers, breast cancer	Some cases of hypereosinophilic syndrome (hes)	Unknown	Unknown	Unknown	Unknown	Bladder cancer	Melanoma
Function	Peptidase, a component of the alternative pathway of	complement activation	ECM protein with possible functions in cell-matrix interactions and matrix assembly.	Peptidase, trypsin inhibitor	Steroidogenesis	Cholesterol metabolism	Role in immunoregulation, binds steroid receptors in complex with Hsp 90 and Hsp70	Cell adhesion and migration along protein fibers within the extracellular matrix (ECM); ECM architecture	Cell-to-cell and cell-to-matrix interactions. Can bind to fibrinogen, fibronectin, laminin, type v collagen and integrins alpha-v/beta-1, alpha- v/beta-3 and alpha-iib/beta-3	Receptor that binds both pdgfa and pdgfb and has a tyrosine-protein kinase activity; mitogen for cells of mesenchymal origin	Unknown	Methyltransferase like 7A; gene expression	Unknown	Unknown	Involved in protein, nucleic acid, carbohydrate, and lipid metabolism, control of gene transcription, growth, development, and differentiation	Active in deacetylating core histone octamers, but inactive in deacetylating nucleosomal histones
Sequence Derived From	NM_001710.1		AL049798	A1088609	NM_000104.2	NM_006227.1	AI753747	Z95331	BF055462	NM_006206.1	AV734646	NM_014033	AK057337	AA058770	NM_022154	NM_003864
Gene Symbol	BF		DPT	P115	CYP1B1	PLTP	FKBP5	FBLN1	THBS1	PDGFRA	FAM26F	DKFZP586A0522	LOC145820	GLCCII	BIGM103	SAP30
Unigene ID	Hs.69771		Hs.80552	Hs.98558	Hs.154654	Hs.439312	Hs.7557	Hs.445240	Hs.164226	Hs.74615	Hs.381220	Hs.288771	Hs.171000	Hs.435806	Hs.284205	Hs.413835
Gene Descriptor	B-factor, properdin		Dermatopontin	Peptidase inhibitor 15	Cytochrome P450, family 1, subfamily B, polypeptide 1	Phospholipid transfer protein	FK506 binding protein 5	Fibulin 1	Thrombospondin 1	Platelet-derived growth factor receptor, alpha polypeptide	Family with sequence similarity 26, member F	DKFZP586A0522 protein; synonyms: AAM B, UbiE	Hypothetical protein LOC145820	Glucocorticoid induced transcript 1	Solute carrier family 39 (zinc transporter), member 8	Sin3-associated polypeptide, 30kDa
Raw Fold	Change 8.41		7.77	4.85	4.63	4.21	4.03	3.50	3.39	3.36	3.28	3.14	3.13	3.11	2.95	2.73
P- Value	0.0007		0.0319	0.0362	0.0401	0.0232	0.0073	0.0474	0.0118	0.0216	0.0443	0.0152	0.0053	0.0069	0.0452	0.0345
Affymetrix Probe Set ID	202357_s_at		213071_at	229947_at	202437_s_at	202075_s_at	224840_at	202994_s_at	201108_s_at	203131_at	229390_at	207761_s_at	1558881_at	227525_at	219869_s_at	204900_x_at
	1		5	3	4	5	9	7	æ	6	10	11	12	13	14	15

Author
Manuscript

4	
ble	
Та	

Author Manuscript

rs
S
n
ъŋ
.Е
<u>eal</u>
þé
J
ų
õ
e,
Ę
0
d t
ē
0a.
ľ
õ
0
ELC.
Ľ
n
ы В
÷
ea
ų
uc
ã
of
Ģ
pe -
e
th
н.
ŝ
ne
e
σ
fe
ıla
B
J.
Ł
ΓM
jo I
5
÷
dc
Ĭ

sease association	tinoblastoma	thma, allergic and lammatory disorders	vodegenerative disorders	known	ıknown	known	ictivated in various icers	east tumor, colon cancer	Josis	ıknown	ithelial tumors, acute eloid and acute nphoid leukemia	intington's disease
Function Di	Cell- cell connections Re	Major neutral protease As present in mast cells inf and is secreted upon the coupled activation- degranulation response of this cell type	Apoptosis and necrotic cell death; accelerates the folding of proteins	Ceramide metabolism Un	Unknown Ur	Cell-cell conectins Un	Suppression of Inc cellular proliferation car	May have a role in a Br signaling pathway; could act as a tumor suppressor.	Unknown Fit	Unknown	Cellular proliferation; Ep mitogenic for my fibroblasts and lyr smooth muscle but not endothelial cells; binds egf receptors	Vesicular transport Hu between the endoplasmic
Sequence Derived From	NM_014459.1	NM_024164	NM_005729	R12678	AL524033	AB028949	NM_006910.1	4862579_RC	AV728526	AI925734	M60278	NM_003827.1
Gene Symbol	PCDH17	TPSB2	PPIF	PHCA	SHARP	KIAA1026	RBBP6	SASHI	MPEG1	Unknown	HBEGF	NAPA
Unigene ID	Hs.106511	Hs.405479	Hs.381072	Hs.23862	Hs.184245	Hs.368823	Hs.188553	Hs.166311	Hs.62264	Hs.448833	Hs.799	Hs.75932
Gene Descriptor	Protocadherin 17	Tryptase beta 2	Peptidylprolyl isomerase F (cyclophilin F)	Phytoceramidase, alkaline	SMART/HDAC1 associated repressor protein	Kazrin	Retinoblastoma binding protein 6	SAM and SH3 domain containing 1	Macrophage expressed gene 1	Similar to nuclear pore complex interacting protein	Heparin-binding epidermal growth factor- like growth factor	N-ethylmaleimide- sensitive factor attachment protein, alpha
Raw Fold Change	-3.67	-3.45	-3.45	-3.15	-3.03	-2.75	-2.57	-2.49	-2.48	-2.42	-2.40	-2.35
P-Value	0.0181	0.0144	0.0214	0.0100	0.0439	0.0368	0.0449	0.0398	0.0229	0.0138	0.0240	0.0001
Affymetrix Probe Set ID	205656_at	207134_x_at	201490_s_at	222688_at	201996_s_at	213478_at	205178_s_at	41644_at	212611_at	221992_at	38037_at	206491_s_at
	1	7	e	4	Ś	9	7	×	6	10	11	12

Author	
Manuscript	

Author
Manus
cript

sociation			's disease, alos syndrome aractic type or	
Disease as		Unknown	Dupuytren Ehlers-Daı dermatosp: VIIC	Unknown
Function	reticulum and the golgi apparatus	Unknown	Collagen catabolism	Chromatin remodeling
Sequence Derived From		BF107618	W60649	AA807344
Gene Symbol		ASBABP2	ADAMTS14	WDR9
Unigene ID		Hs.440769	Hs.352156	Hs.435904
Gene Descriptor		A specific BCL2 ARE- binding protein 2	A disintegrin-like and metalloprotease with thrombospondin type 1 motif, 14	WD repeat domain 9
Raw Fold Change		-2.30	-2.27	-2.26
P-Value		0.0432	0.0087	0.0123
Affymetrix Probe Set ID		224940_s_at	230167_at	231960_at
		13	14	15